Privileged structures - dream or reality: preferential organization of azanaphthalene scaffold.
暂无分享,去创建一个
J Polanski | A Kurczyk | A Bak | R Musiol | J. Polanski | A. Bąk | R. Musioł | A. Kurczyk
[1] Yuhua Chen,et al. Vasodilatation produced by fasudil mesylate in vivo and in vitro. , 2011, Vascular pharmacology.
[2] Tudor I. Oprea,et al. Property distribution of drug-related chemical databases* , 2000, J. Comput. Aided Mol. Des..
[3] Ichiro Katayama,et al. Emedastine difumarate: a review of its potential ameliorating effect for tissue remodeling in allergic diseases , 2009, Expert opinion on pharmacotherapy.
[4] P. R. Vuddanda,et al. Berberine: a potential phytochemical with multispectrum therapeutic activities , 2010, Expert opinion on investigational drugs.
[5] D. MacMillan,et al. Enantioselective organocatalytic indole alkylations. Design of a new and highly effective chiral amine for iminium catalysis. , 2002, Journal of the American Chemical Society.
[6] Dan C. Fara,et al. Lead-like, drug-like or “Pub-like”: how different are they? , 2007, J. Comput. Aided Mol. Des..
[7] Jürgen Bajorath,et al. Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.
[8] B F King,et al. In search of selective P2 receptor ligands: interaction of dihydropyridine derivatives at recombinant rat P2X(2) receptors. , 2000, Journal of the autonomic nervous system.
[9] George Karypis,et al. Common Pharmacophore Identification Using Frequent Clique Detection Algorithm , 2009, J. Chem. Inf. Model..
[10] Samuel I Stupp,et al. Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin. , 2011, ACS nano.
[11] Miklos Feher,et al. Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..
[12] C. Kamei,et al. Anticonvulsant Properties of 1,4-Benzodiazepine Derivatives in Amygdaloid-Kindled Seizures and Their Chemical Structure-Related Anticonvulsant Action , 1998, Pharmacology.
[13] Stephan B Felix,et al. Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application , 2009, Expert opinion on drug metabolism & toxicology.
[14] Manuel Urbano-Cuadrado,et al. Computational medicinal chemistry in fragment-based drug discovery: what, how and when. , 2011, Future medicinal chemistry.
[15] M. Murcko,et al. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. , 2008, Journal of medicinal chemistry.
[16] Jörg Rademann,et al. Design of chemical libraries with potentially bioactive molecules applying a maximum common substructure concept , 2009, Molecular Diversity.
[17] Jürgen Bajorath,et al. Mining of Randomly Generated Molecular Fragment Populations Uncovers Activity-Specific Fragment Hierarchies , 2007, J. Chem. Inf. Model..
[18] Eliezer J Barreiro,et al. Privileged structures: a useful concept for the rational design of new lead drug candidates. , 2007, Mini reviews in medicinal chemistry.
[19] M. Finn,et al. 2,6-Dichloro-9-thiabicyclo[3.3.1]nonane: a privileged, bivalent scaffold for the display of nucleophilic components. , 2001, The Journal of organic chemistry.
[20] R G Smith,et al. Synthesis and biological activities of phenyl piperazine-based peptidomimetic growth hormone secretagogues. , 1998, Bioorganic & medicinal chemistry letters.
[21] Ronni Wolf,et al. Quinine sulfate and HSV replication. , 2003, Dermatology online journal.
[22] Tracy T Batchelor,et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. , 2011, Cancer research.
[23] Eugen Lounkine,et al. Random molecular fragment methods in computational medicinal chemistry. , 2008, Current medicinal chemistry.
[24] Philip J. Hajduk,et al. Fragment-based lead discovery: challenges and opportunities , 2011, J. Comput. Aided Mol. Des..
[25] Joseph M. Blandeau. Expanded activity and utility of the new fluoroquinolones: A review , 1999 .
[26] Veerabahu Shanmugasundaram,et al. Molecular similarity measures. , 2011, Methods in molecular biology.
[27] François Nosten,et al. The reality of using primaquine , 2010, Malaria Journal.
[28] Gisbert Schneider,et al. SVM-Based Feature Selection for Characterization of Focused Compound Collections , 2004, J. Chem. Inf. Model..
[29] H Hunt Batjer,et al. Endovascular treatment strategies for cerebral vasospasm. , 2006, Neurosurgical focus.
[30] Brigitte Frey Tirri,et al. Antimicrobial Topical Agents Used in the Vagina , 2011 .
[31] T. O'Brien,et al. Fragment-based drug discovery. , 2004, Journal of medicinal chemistry.
[32] Silvia Letasiová,et al. Antiproliferative activity of berberine in vitro and in vivo. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[33] F. Vincenti,et al. Sotrastaurin, a Novel Small Molecule Inhibiting Protein‐Kinase C: Randomized Phase II Study in Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[34] K. Chapman,et al. Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. , 2002, Bioorganic & medicinal chemistry letters.
[35] Qian Wang,et al. In vivo and in vitro antiviral effects of berberine on influenza virus , 2011, Chinese journal of integrative medicine.
[36] Elisabeth Heath,et al. Cediranib inhibits both the intraosseous growth of PDGF D‐Positive prostate cancer cells and the associated bone reaction , 2012, The Prostate.
[37] Oriana Tabarrini,et al. 6-desfluoroquinolones as HIV-1 Tat-mediated transcription inhibitors. , 2010, Future medicinal chemistry.
[38] Michèle N Schulz,et al. Recent progress in fragment-based lead discovery. , 2009, Current opinion in pharmacology.
[39] Iwao Ojima,et al. Modern natural products chemistry and drug discovery. , 2008, Journal of medicinal chemistry.
[40] W. Guida,et al. The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.
[41] G. Marshall,et al. Privileged scaffolds targeting reverse-turn and helix recognition , 2008, Expert opinion on therapeutic targets.
[42] J Polanski,et al. Quinoline-based antifungals. , 2010, Current medicinal chemistry.
[43] Gisbert Schneider,et al. Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.
[44] Peter W Swaan,et al. Camptothecins , 2012, Drugs.
[45] Arthur M. Doweyko,et al. QSAR: dead or alive? , 2008, J. Comput. Aided Mol. Des..
[46] K C Nicolaou,et al. Discovery of Novel Antibacterial Agents Active Against Methicillin‐Resistant Staphylococcus aureus from Combinatorial Benzopyran Libraries , 2001, Chembiochem : a European journal of chemical biology.
[47] P. Hajduk,et al. Privileged molecules for protein binding identified from NMR-based screening. , 2000, Journal of medicinal chemistry.
[48] Yves Pommier,et al. Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. , 2004, Current medicinal chemistry. Anti-cancer agents.
[49] Matthew Clark,et al. Generalized Fragment-Substructure Based Property Prediction Method , 2005, J. Chem. Inf. Model..
[50] Alexander Tropsha,et al. Recent Advances in Development, Validation, and Exploitation of QSAR Models , 2010, Burger's Medicinal Chemistry and Drug Discovery.
[51] Clayton Springer,et al. CoMFA and HQSAR of acylhydrazide cruzain inhibitors. , 2002, Bioorganic & medicinal chemistry letters.
[52] Michal Vieth,et al. Drugs in other drugs: a new look at drugs as fragments. , 2007, Drug discovery today.
[53] G. Bemis,et al. A minimalist approach to fragment‐based ligand design using common rings and linkers: Application to kinase inhibitors , 2004, Proteins.
[54] R. Govindan,et al. Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097) , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[55] A. Caflisch,et al. Automatic and efficient decomposition of two-dimensional structures of small molecules for fragment-based high-throughput docking. , 2006, Journal of medicinal chemistry.
[56] R. Desimone,et al. Privileged structures: applications in drug discovery. , 2004, Combinatorial chemistry & high throughput screening.
[57] J. Larkin,et al. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours , 2011, British Journal of Cancer.
[58] S Garattini,et al. Are me-too drugs justified? , 1997, Journal of nephrology.
[59] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[60] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .
[61] Christophe Cleva,et al. Chemical substructures in drug discovery. , 2003, Drug discovery today.
[62] H. Mackay,et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.
[63] Junmei Wang,et al. GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search , 2007, J. Chem. Inf. Model..
[64] Gerhard Reichel,et al. [Muscle cramps--differential diagnosis and therapy]. , 2009, Medizinische Monatsschrift fur Pharmazeuten.
[65] Jeremy L. Jenkins,et al. Clustering and Rule-Based Classifications of Chemical Structures Evaluated in the Biological Activity Space , 2007, J. Chem. Inf. Model..
[66] Stefan Wetzel,et al. Role of Natural Products in Drug Discovery , 2010 .
[67] Yukihito Higashi,et al. Rho-Associated Kinase Activity, Endothelial Function, and Cardiovascular Risk Factors , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[68] Derek S. Tan,et al. Diversity-oriented synthesis: exploring the intersections between chemistry and biology , 2005, Nature chemical biology.
[69] Gregory Piatetsky-Shapiro,et al. Knowledge Discovery in Databases: An Overview , 1992, AI Mag..
[70] R. Shoemaker,et al. β-Diketo Acid Pharmacophore Hypothesis. 1. Discovery of a Novel Class of HIV-1 Integrase Inhibitors , 2005 .
[71] A. Schuffenhauer,et al. Chemical diversity and biological activity , 2006 .
[72] Imran Ahmad,et al. Development and characterization of a novel liposome-based formulation of SN-38. , 2004, International journal of pharmaceutics.
[73] Johan Vallon-Christersson,et al. Open Access Research , 2022 .
[74] Dvornik Dm. Tissue selective inhibition of prostaglandin biosynthesis by etodolac. , 1997 .
[75] Hugo Kubinyi,et al. Chemical similarity and biological activities , 2002 .
[76] Sophie Gale,et al. 28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics. , 2010, IDrugs : the investigational drugs journal.
[77] Katrin Stierand,et al. From Structure Diagrams to Visual Chemical Patterns , 2010, J. Chem. Inf. Model..
[78] D. Harmon,et al. Effect of ergot alkaloids on contractility of bovine right ruminal artery and vein. , 2011, Journal of animal science.
[79] Iwao Kuwajima. [Antihypertensive effects of nifedipine and changing for modified-release formula]. , 2006, Drugs.
[80] D. Newell,et al. Neurointerventional treatment of vasospasm , 2006, Neurological research.
[81] Didier Rognan,et al. Assessing the Scaffold Diversity of Screening Libraries , 2006, J. Chem. Inf. Model..
[82] Gerhard Zenke,et al. The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation , 2009, Journal of Pharmacology and Experimental Therapeutics.
[83] Jean-Francois Marier,et al. Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors. , 2011, Journal of pharmaceutical sciences.
[84] B. Grzybowski,et al. The 'wired' universe of organic chemistry. , 2009, Nature chemistry.
[85] W. Dinsmore,et al. Available and future treatments for erectile dysfunction. , 2005, Clinical cornerstone.
[86] Markus Wagener,et al. Potential Drugs and Nondrugs: Prediction and Identification of Important Structural Features , 2000, J. Chem. Inf. Comput. Sci..
[87] Isabelle Krimm,et al. Ligand specificity, privileged substructures and protein druggability from fragment-based screening. , 2011, Current opinion in chemical biology.
[88] Anatoly G. Artemenko,et al. Virtual Screening and Molecular Design Based on Hierarchical Qsar Technology , 2009, Recent Advances in QSAR Studies.
[89] P. LoRusso,et al. Poly(ADP-Ribose) Polymerase Inhibitors: A Novel Drug Class With a Promising Future , 2010, Cancer journal.
[90] A. Caflisch,et al. Fragment-Based Flexible Ligand Docking by Evolutionary Optimization , 2001, Biological chemistry.
[91] S. Eliasof,et al. CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development , 2011, Current bioactive compounds.
[92] Maria Laura Bolognesi,et al. The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases , 2011, Expert opinion on drug discovery.
[93] Christophe Biot,et al. Ferroquine: a new weapon in the fight against malaria , 2004 .
[94] Arvind Saklani,et al. Plant-derived compounds in clinical trials. , 2008, Drug discovery today.
[95] R. O'brien,et al. Development of fluoroquinolones as first-line drugs for tuberculosis--at long last! , 2003, American journal of respiratory and critical care medicine.
[96] J Rosenthal,et al. Nilvadipine: profile of a new calcium antagonist. An overview. , 1994, Journal of cardiovascular pharmacology.
[97] E. Barreiro,et al. From nature to drug discovery: the indole scaffold as a 'privileged structure'. , 2009, Mini reviews in medicinal chemistry.
[98] John J. M. Wiener,et al. Scaffold explorer: an interactive tool for organizing and mining structure-activity data spanning multiple chemotypes. , 2010, Journal of medicinal chemistry.
[99] Jong-Bae Kim,et al. In vitro antibacterial activity of echinomycin and a novel analogue, YK2000, against vancomycin-resistant enterococci. , 2004, International journal of antimicrobial agents.
[100] V. Solomon,et al. Quinoline as a privileged scaffold in cancer drug discovery. , 2011, Current medicinal chemistry.
[101] A. Dowson,et al. Review of zolmitriptan and its clinical applications in migraine , 2002, Expert opinion on pharmacotherapy.
[102] Ian A. Watson,et al. Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.
[103] Gisbert Schneider,et al. Properties and Architecture of Drugs and Natural Products Revisited , 2007 .
[104] Ian M. Scott,et al. Extracts of Canadian First Nations Medicinal Plants, Used as Natural Products, Inhibit Neisseria gonorrhoeae Isolates With Different Antibiotic Resistance Profiles , 2011, Sexually transmitted diseases.
[105] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[106] Hong Zhao,et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. , 2008, Bioconjugate chemistry.
[107] Jaroslaw Polanski,et al. Mapping fragmental drug-likeness in the MoStBioDat environment: intramolecular hydrogen bonding motifs in β-ketoenols. , 2011, Combinatorial chemistry & high throughput screening.
[108] Andrew R. Leach,et al. Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..
[109] A. Tutt,et al. PARP inhibitors--current status and the walk towards early breast cancer. , 2011, Breast.
[110] Solomon Habtemariam,et al. The Therapeutic Potential of Berberis darwinii Stem-Bark: Quantification of Berberine and In Vitro Evidence for Alzheimer's Disease Therapy , 2011, Natural product communications.
[111] A. B. Benson,et al. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma , 2008, Cancer Chemotherapy and Pharmacology.
[112] Helen J. Mitchell,et al. Natural Product-like Combinatorial Libraries Based on Privileged Structures. 1. General Principles and Solid-Phase Synthesis of Benzopyrans , 2000 .
[113] Uwe Fuhr,et al. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors , 2011, Clinical pharmacokinetics.
[114] A. Emmerson,et al. The quinolones: decades of development and use. , 2003, The Journal of antimicrobial chemotherapy.
[115] Valerie J. Gillet,et al. SPROUT, HIPPO and CAESA: Tools for de novo structure generation and estimation of synthetic accessibility , 1995 .
[116] J. Block,et al. Raynaud's phenomenon , 2001, The Lancet.
[117] Alexander Hillisch,et al. In Silico ADMET Traffic Lights as a Tool for the Prioritization of HTS Hits , 2006, ChemMedChem.
[118] Raimund Mannhold,et al. Calculation of Drug Lipophilicity: The Hydrophobic Fragmental Constant Approach , 1992 .
[119] P. Beroza,et al. Target-related affinity profiling: Telik's lead discovery technology. , 2005, Current topics in medicinal chemistry.
[120] Peter Neuhaus,et al. Sotrastaurin single‐dose pharmacokinetics in de novo liver transplant recipients , 2011, Transplant international : official journal of the European Society for Organ Transplantation.
[121] Seung Joon Baek,et al. Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. , 2007, Cancer letters.
[122] D. J. Russell,et al. Structure-activity studies of echinomycin antibiotics against drug-resistant and biofilm-forming Staphylococcus aureus and Enterococcus faecalis. , 2009, Bioorganic & medicinal chemistry letters.
[123] Douglas A. Horton,et al. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. , 2003, Chemical reviews.
[124] Edward R Zartler,et al. Fragonomics: fragment-based drug discovery. , 2005, Current opinion in chemical biology.
[125] Joseph Varon,et al. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. , 2012, The American journal of emergency medicine.
[126] M. Prakash Hande,et al. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability , 1999, Nature Genetics.
[127] Chia-Chi Lin,et al. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer. , 2010, Discovery medicine.
[128] Yoshihiro Fukumoto,et al. Recent progress in the management of pulmonary hypertension. , 2011, Circulation journal : official journal of the Japanese Circulation Society.
[129] G. Schneider,et al. Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.
[130] Michael M. Hann,et al. RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..
[131] Mario Jiménez-Hernández,et al. Treatment of Raynaud's phenomenon. , 2008, Autoimmunity reviews.
[132] J. Bajorath,et al. Systematic analysis of public domain compound potency data identifies selective molecular scaffolds across druggable target families. , 2010, Journal of medicinal chemistry.
[133] Jaroslaw Polanski,et al. Receptor dependent multidimensional QSAR for modeling drug--receptor interactions. , 2009, Current medicinal chemistry.
[134] J Jaworska,et al. How can structural similarity analysis help in category formation? , 2007, SAR and QSAR in environmental research.
[135] Andreas Bender,et al. Molecular Similarity Searching Using Atom Environments, Information-Based Feature Selection, and a Naïve Bayesian Classifier , 2004, J. Chem. Inf. Model..
[136] Tudor I. Oprea,et al. Model-Free Drug-Likeness from Fragments , 2010, J. Chem. Inf. Model..
[137] Federico Corelli,et al. The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry. , 2009, Current medicinal chemistry.
[138] Mayank Goel,et al. Intravenous Diazepam, Midazolam and Lorazepam in Acute Seizure Control , 2012, The Indian Journal of Pediatrics.
[139] Jaroslaw Polanski,et al. Neural Nets for the Simulation of Molecular Recognition within MS-Windows Environment , 1996, J. Chem. Inf. Comput. Sci..
[140] D. Fattori,et al. Molecular recognition: the fragment approach in lead generation. , 2004, Drug discovery today.
[141] A. Ganesan. The impact of natural products upon modern drug discovery. , 2008, Current opinion in chemical biology.
[142] N. Taira,et al. [Nifedipine: a novel vasodilator]. , 2006, Drugs.
[143] Zena Wilson,et al. Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family , 2011, Molecular Cancer Therapeutics.
[144] Thirunavukkarasu Arun Babu,et al. Buclizine is back again! This time as a pediatric appetite stimulant , 2011, Indian journal of pharmacology.
[145] H Denys,et al. PARP INHIBITORS IN ONCOLOGY: A NEW SYNTHETIC LETHAL APPROACH TO CANCER THERAPY , 2011, Acta clinica Belgica.
[146] F. Zunino,et al. Current status and perspectives in the development of camptothecins. , 2002, Current pharmaceutical design.
[147] Matthew E Welsch,et al. Privileged scaffolds for library design and drug discovery. , 2010, Current opinion in chemical biology.
[148] Marvin Johnson,et al. Concepts and applications of molecular similarity , 1990 .
[149] Jürgen Bajorath,et al. Assessment of Molecular Similarity from the Analysis of Randomly Generated Structural Fragment Populations , 2006, J. Chem. Inf. Model..
[150] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[151] Raffaele Izzo,et al. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia , 2010, Journal of hypertension.
[152] Patricia Kraft,et al. Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin’s lymphoma , 2009, Haematologica.
[153] Wolfgang Guba,et al. Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.
[154] Andrew Good,et al. Approaches to target class combinatorial library design. , 2004, Methods in molecular biology.
[155] S. Khan,et al. A brief history of malaria chemotherapy. , 2010, The journal of the Royal College of Physicians of Edinburgh.
[156] Fumihiko Kajiya,et al. Cardioprotective effect of hydroxyfasudil as a specific Rho-kinase inhibitor, on ischemia-reperfusion injury in canine coronary microvessels in vivo. , 2006, Clinical hemorheology and microcirculation.
[157] Ian A. Watson,et al. Characteristic physical properties and structural fragments of marketed oral drugs. , 2004, Journal of medicinal chemistry.
[158] G. Bemis,et al. Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.
[159] Hiroshi Matsuda,et al. Effect of nilvadipine on regional cerebral blood flow in a patient with early Alzheimer disease. , 2008, Clinical nuclear medicine.
[160] Thomas Bäck,et al. Mining a Chemical Database for Fragment Co-occurrence: Discovery of "Chemical Clichés" , 2006, J. Chem. Inf. Model..
[161] Arup K. Ghose,et al. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[162] Peter Ertl,et al. Cheminformatics analysis of natural products: lessons from nature inspiring the design of new drugs. , 2008, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[163] Paul Labute,et al. Detection and assignment of common scaffolds in project databases of lead molecules. , 2009, Journal of medicinal chemistry.
[164] Andrea Cipriani,et al. Hydroxyzine for generalised anxiety disorder. , 2010, The Cochrane database of systematic reviews.
[165] Gradman Ah. The evolving role of calcium channel blockers in the treatment of angina pectoris: focus on felodipine. , 1995 .
[166] Jhon J. Rojas,et al. Screening for antimicrobial activity of ten medicinal plants used in Colombian folkloric medicine: A possible alternative in the treatment of non-nosocomial infections , 2006, BMC complementary and alternative medicine.
[167] A. Dhir,et al. Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders , 2010, Phytotherapy research : PTR.
[168] A. Escobedo,et al. Hospitalization of Cuban children for giardiasis: a retrospective study in a paediatric hospital in Havana , 2011, Annals of tropical medicine and parasitology.
[169] Uwe Dr Petersen,et al. Quinolone Antibiotics: The Development of Moxifloxacin , 2006 .
[170] G. Klopman,et al. Computer automated structure evaluation (CASE) of flavonoids as larval growth inhibitors , 1988 .
[171] R. Owens,et al. Antimicrobial safety: focus on fluoroquinolones. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[172] Xuechu Zhen,et al. Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. , 2008, Bioorganic & medicinal chemistry.
[173] Teodoro S. Kaufman,et al. Die Jagd auf Chinin: Etappenerfolge und Gesamtsiege , 2005 .
[174] A. Escobedo,et al. Mebendazole in parasitic infections other than those caused by soil-transmitted helminths. , 2009, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[175] Ajay,et al. Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.
[176] Kimito Funatsu,et al. Novel Canonical Coding Method for Representation of Three-Dimensional Structures , 2000, J. Chem. Inf. Comput. Sci..
[177] N. Agarwal,et al. Novel molecular targets for the therapy of castration-resistant prostate cancer. , 2012, European urology.
[178] R Wise,et al. Norfloxacin--a review of pharmacology and tissue penetration. , 1984, The Journal of antimicrobial chemotherapy.
[179] W. Couldwell,et al. Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage , 2005, Neurocritical care.
[180] P. Schultz,et al. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. , 1999, Chemistry & biology.
[181] C. Dobson. Chemical space and biology , 2004, Nature.
[182] Christina Plaisier,et al. Berberine acutely activates the glucose transport activity of GLUT1. , 2011, Biochimie.
[183] Adriaan P. IJzerman,et al. Computational Approaches to Fragment and Substructure Discovery and Evaluation , 2008 .
[184] Tudor I. Oprea,et al. Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..
[185] A. Michiel van Rhee,et al. Use of Recursion Forests in the Sequential Screening Process: Consensus Selection by Multiple Recursion Trees , 2003, J. Chem. Inf. Comput. Sci..
[186] Tao Jiang,et al. A maximum common substructure-based algorithm for searching and predicting drug-like compounds , 2008, ISMB.
[187] Dora M Schnur,et al. Are target-family-privileged substructures truly privileged? , 2006, Journal of medicinal chemistry.
[188] M. Jacobson,et al. Binding-Site Assessment by Virtual Fragment Screening , 2010, PloS one.
[189] Yun Yen,et al. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. , 2012, Nanomedicine : nanotechnology, biology, and medicine.
[190] R. Glen,et al. Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.
[191] J. Ring,et al. Demonstration of quinolone phototoxicity in vitro. , 1990, Dermatologica.
[192] Junling Han,et al. Modulating gut microbiota as an anti-diabetic mechanism of berberine , 2011, Medical science monitor : international medical journal of experimental and clinical research.
[193] G Klopman,et al. Quantitative structure-activity relationships of beta-adrenergic agents. Application of the computer automated structure evaluation (CASE) technique of molecular fragment recognition. , 1986, Journal of theoretical biology.
[194] Tudor I. Oprea,et al. Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.
[195] Patricia Kraft,et al. Novel Delivery of SN38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11–Refractory Model , 2008, Clinical Cancer Research.
[196] J. Robinson,et al. Evaluation of French Guiana traditional antimalarial remedies. , 2005, Journal of ethnopharmacology.
[197] Tait Shanafelt,et al. Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia , 2010, Leukemia & lymphoma.
[198] Y. You,et al. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. , 2005, Journal of medicinal food.
[199] Robert P. Sheridan,et al. Chemical Similarity Using Physiochemical Property Descriptors , 1996, J. Chem. Inf. Comput. Sci..
[200] Daniel J. Freeman,et al. Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives. , 2011, Journal of medicinal chemistry.
[201] G. Poirier,et al. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. , 1999, The Biochemical journal.
[202] P. McDermott,et al. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals. , 2006, Veterinary journal.
[203] Karl Swedberg,et al. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals , 2011, Journal of hypertension.
[204] P. Hajduk,et al. A decade of fragment-based drug design: strategic advances and lessons learned , 2007, Nature Reviews Drug Discovery.
[205] H. Katz,et al. Quinine-Induced Hypoglycemia , 1993, Annals of Internal Medicine.
[206] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[207] W. Foulkes,et al. BRCA1 and BRCA2: 1994 and beyond , 2004, Nature Reviews Cancer.
[208] Jianjun Cheng,et al. Antitumor Activity of β-Cyclodextrin Polymer−Camptothecin Conjugates , 2004 .
[209] Claus Bachert,et al. Efficacy of Second-Generation Antihistamines in Patients with Allergic Rhinitis and Comorbid Asthma , 2011, The Journal of asthma : official journal of the Association for the Care of Asthma.
[210] Joseph C. Lin. Rule of Three: a case of discrimination against certain authors caused by the cataloging rules , 1985 .
[211] H Matter,et al. Computational approaches towards the rational design of drug-like compound libraries. , 2001, Combinatorial chemistry & high throughput screening.
[212] H. Kubinyi,et al. A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.
[213] Haruki Nakamura,et al. Definition of Drug-Likeness for Compound Affinity , 2011, J. Chem. Inf. Model..
[214] Frederick P. Roth,et al. Chemical substructures that enrich for biological activity , 2008, Bioinform..
[215] Satoru Todo,et al. Sotrastaurin, a new selective protein kinase C inhibitor, on the way. , 2012, Transplantation.
[216] A. Hopkins,et al. Navigating chemical space for biology and medicine , 2004, Nature.
[217] Yuebo Zhang,et al. Berberine inhibits PTP1B activity and mimics insulin action. , 2010, Biochemical and biophysical research communications.
[218] Robert P Bywater,et al. Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.
[219] M. Bolon,et al. Newer fluoroquinolones , 2009, Infectious disease clinics of North America.
[220] R. Venkataraghavan,et al. Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..
[221] Carol A Barnes,et al. Peripheral delivery of a ROCK inhibitor improves learning and working memory. , 2009, Behavioral neuroscience.
[222] Kazunori Takada,et al. Camptothecin (CPT) directly binds to human heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) and inhibits the hnRNP A1/topoisomerase I interaction. , 2011, Bioorganic & medicinal chemistry.
[223] Robert C. Glen,et al. Novel Methods for the Prediction of logP, pKa, and logD , 2002, J. Chem. Inf. Comput. Sci..
[224] S. Meshnick,et al. Is chloroquine making a comeback? , 2011, The Journal of infectious diseases.
[225] Padhraic Smyth,et al. From Data Mining to Knowledge Discovery in Databases , 1996, AI Mag..
[226] F H Allen,et al. Intramolecular hydrogen bonds: common motifs, probabilities of formation and implications for supramolecular organization. , 2000, Acta crystallographica. Section B, Structural science.
[227] John Heritage,et al. Measurement of ampicillin, vancomycin, linezolid and gentamicin activity against enterococcal biofilms. , 2006, The Journal of antimicrobial chemotherapy.
[228] Masahiro Fukuoka,et al. Gefitinib in non-small cell lung cancer , 2005, Expert opinion on pharmacotherapy.
[229] B. E. Evans,et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.
[230] G. J. M. Parker,et al. A two-part Phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics , 2011, Cancer Chemotherapy and Pharmacology.
[231] D. Ettlinger,et al. Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer. , 2011, Anticancer research.
[232] Gisbert Schneider,et al. Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.
[233] J. Damber,et al. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer , 2009, British Journal of Cancer.
[234] Yoshihiro Fukumoto,et al. Rho-kinase: important new therapeutic target in cardiovascular diseases. , 2011, American journal of physiology. Heart and circulatory physiology.
[235] Jaroslaw Polanski,et al. The Receptor-like Neural Network for Modeling Corticosteroid and Testosterone Binding Globulins , 1997, J. Chem. Inf. Comput. Sci..
[236] K. Hatzimouratidis,et al. A Comparative Review of the Options for Treatment of Erectile Dysfunction , 2012, Drugs.
[237] Daniel J. Graham,et al. Information Content in Organic Molecules: Quantification and Statistical Structure via Brownian Processing , 2004, J. Chem. Inf. Model..
[238] M. Fiałkowski,et al. Architecture and evolution of organic chemistry. , 2005, Angewandte Chemie.
[239] Roberto Todeschini,et al. Molecular descriptors for chemoinformatics , 2009 .
[240] Nouri Neamati,et al. HIV-1 IN strand transfer chelating inhibitors: a focus on metal binding. , 2011, Molecular pharmaceutics.
[241] B. Shoichet,et al. A specific mechanism of nonspecific inhibition. , 2003, Journal of medicinal chemistry.
[242] Ju-Yeon Lee,et al. Combinatorial Library Synthesis and Biological Evaluation of Pyrazolo[4,3‐e][1,4]diazepine as a Potential Privileged Structure , 2009, ChemMedChem.
[243] Mary Anne Jackson,et al. The Use of Systemic and Topical Fluoroquinolones , 2011, Pediatrics.
[244] Vic Velanovich,et al. Esomeprazole: a proton pump inhibitor , 2009, Expert review of gastroenterology & hepatology.
[245] C. Ogilvy,et al. Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. , 2005, Neurosurgery clinics of North America.
[246] Hye-Sook Kim,et al. Synthesis and Biological Activity of Fatty Acid Derivatives of Quinine , 2005, Bioscience, biotechnology, and biochemistry.
[247] Y. Pommier. Topoisomerase I inhibitors: camptothecins and beyond , 2006, Nature Reviews Cancer.
[248] A. Shields,et al. Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study , 2011, Investigational New Drugs.
[249] G. Klopman. Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules , 1985 .
[250] M. Ranson,et al. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours , 2012, British Journal of Cancer.
[251] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[252] David J Triggle,et al. The chemist as astronaut: searching for biologically useful space in the chemical universe. , 2009, Biochemical pharmacology.
[253] R. Ronimus,et al. The composition of Ehrlich's salvarsan: resolution of a century-old debate. , 2005, Angewandte Chemie.
[254] A. Ghose,et al. Knowledge-based chemoinformatic approaches to drug discovery. , 2006, Drug discovery today.
[255] Ola Engkvist,et al. Molecular Topology Analysis of the Differences between Drugs, Clinical Candidate Compounds, and Bioactive Molecules , 2010, J. Chem. Inf. Model..
[256] Jürgen Bajorath,et al. Chemical Database Mining through Entropy-Based Molecular Similarity Assessment of Randomly Generated Structural Fragment Populations , 2007, J. Chem. Inf. Model..
[257] Daniela Barlocco,et al. Privileged Structures as Leads in Medicinal Chemistry , 2006 .
[258] Luca Sartori,et al. Identification and Selection of "Privileged Fragments" Suitable for Primary Screening , 2008, J. Chem. Inf. Model..
[259] Maksimov Ml,et al. [Application of AT1-angiotensin II receptor blocker valsartan in clinical practice]. , 2011 .
[260] Lorenz C. Blum,et al. Chemical space as a source for new drugs , 2010 .
[261] Jiří Špaček,et al. A Comparison of Dequalinium Chloride Vaginal Tablets (Fluomizin®) and Clindamycin Vaginal Cream in the Treatment of Bacterial Vaginosis: A Single-Blind, Randomized Clinical Trial of Efficacy and Safety , 2011, Gynecologic and Obstetric Investigation.
[262] Lin Wu,et al. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. , 2008, Heart rhythm.
[263] Eugen Lounkine,et al. Mapping of Activity-Specific Fragment Pathways Isolated from Random Fragment Populations Reveals the Formation of Coherent Molecular Cores , 2007, J. Chem. Inf. Model..
[264] Thomas Becker,et al. The Novel Immunosuppressive Protein Kinase C Inhibitor Sotrastaurin Has No Pro-Viral Effects on the Replication Cycle of Hepatitis B or C Virus , 2011, PloS one.
[265] Harren Jhoti,et al. Pyramid: An Integrated Platform for Fragment‐based Drug Discovery , 2006 .
[266] Hugo Kubinyi,et al. Privileged Structures and Analogue‐Based Drug Discovery , 2006 .
[267] Tudor I. Oprea. Current trends in lead discovery: Are we looking for the appropriate properties? , 2002, J. Comput. Aided Mol. Des..
[268] Chris L. Waller,et al. A Comparative QSAR Study Using CoMFA, HQSAR, and FRED/SKEYS Paradigms for Estrogen Receptor Binding Affinities of Structurally Diverse Compounds , 2004, J. Chem. Inf. Model..